By Ian Walker

AstraZeneca PLC on Wednesday priced a six-part $7 billion global bond offering, which will be used to pay part of its acquisition of Alexion Pharmaceuticals Inc.

The pharmaceutical giant, which agreed to buy Boston-based Alexion Pharmaceuticals last December for $39 billion in cash and stock, said it will also use any money raised to repay or refinance part of Alexion's debt, as well as for general corporate purposes.

The notes, which carry coupons of between 0.3% and 3.0%, mature between May 26, 2023 and May 28, 2051.

On Tuesday the U.K. Competition and Markets Authority said that it was considering whether AstraZeneca's acquisition of Alexion would lessen competition within the U.K., and invited comments from interested parties ahead of a final decision.

The regulator said interested parties have until June 3 to offer their comments. It has set a deadline of July 21 for a Phase 1 decision on the deal.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

May 26, 2021 02:30 ET (06:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Alexion Pharmaceuticals (NASDAQ:ALXN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Alexion Pharmaceuticals.